Plain-English translation of NCT07434726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
When your heart stops beating while you're in the hospital, doctors use emergency procedures called Advanced Cardiac Life Support (ACLS) to try to restart it. This trial is testing whether adding a new technique called REBOA — which uses a small balloon catheter placed in a major artery to improve blood flow to vital organs during resuscitation — helps save more lives than standard treatment alone.
In-hospital cardiac arrest is life-threatening, and even with the best current treatments, many patients do not survive. Researchers believe that the balloon catheter technique might help by redirecting blood flow to the heart and brain during resuscitation, potentially improving outcomes.
You likely qualify if…
You likely don't qualify if…
If you experience cardiac arrest in the hospital, the resuscitation team will immediately begin standard emergency heart restart procedures. At the same time, a research team will assess whether you qualify for the study. If you do, you will be randomly assigned to receive either the standard treatment alone or the standard treatment plus the balloon catheter technique. After stabilization, you would receive the usual follow-up care for cardiac arrest patients, and the research team would track your recovery and outcomes.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
Switzerland
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment target
~98 participants
Started
April 2026
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tanja Birrenbach, MD, MME
Inselspital University Hospital Bern
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.